Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression
文献类型：期刊论文
| 作者 | Yu, Dandan3; Zhang, Yong1; Chen, Gege3; Xie, Yongsheng3; Xu, Zhijian1 ; Chang, Shuaikang3; Hu, Liangning3; Li, Bo1; Bu, Wenxuan3; Wang, Yingcong3
|
| 刊名 | ACTA BIOCHIMICA ET BIOPHYSICA SINICA
 |
| 出版日期 | 2018-08 |
| 卷号 | 50期号:8页码:782-792 |
| 关键词 | mantle cell lymphoma pterostilbene antiproliferative activity PI3K/Akt/mTOR pathway synergistic cytotoxicity |
| ISSN号 | 1672-9145 |
| DOI | 10.1093/abbs/gmy070 |
| 文献子类 | Article |
| 英文摘要 | Mantle cell lymphoma (MCL) is an aggressive and mostly incurable B-cell malignancy with frequent relapses after an initial response to standard chemotherapy. Therefore, novel therapies are urgently required to improve MCL clinical outcomes. In this study, MCL cell lines were treated with pterostilbene (PTE), a non-toxic natural phenolic compound primarily found in blueberries. The antitumor activity of PTE was examined by using the Cell Counting Kit-8, apoptosis assays, cell cycle analysis, JC-1 mitochondrial membrane potential assay, western blot analysis, and tumor xenograft models. PTE treatment induced a dose-dependent inhibition of cell proliferation, including the induction of cell apoptosis and cell cycle arrest at the G0/G1 phase. Moreover, the PI3K/Akt/mTOR pathway was downregulated after PTE treatment, which might account for the anti-MCL effects of PTE. Synergistic cytotoxicity was also observed, both in MCL cells and in xenograft mouse models, when PTE was administered in combination with bortezomib (BTZ). The antitumor effects of PTE shown in our study provide an innovative option for MCL patients with poor responses to standardized therapy. It is noteworthy that the treatment combining PTE with BTZ warrants clinical investigation, which may offer an alternative and effective MCL treatment in the future. |
| WOS关键词 | PROTEIN-KINASE PATHWAY ; COLON-CANCER CELLS ; PROSTATE-CANCER ; IN-VITRO ; TRANSDUCTION PATHWAYS ; BORTEZOMIB RESISTANCE ; CYCLE ARREST ; APOPTOSIS ; ACTIVATION ; PATHOGENESIS |
| 资助项目 | National Natural Science Foundation of China[81570190] ; National Natural Science Foundation of China[81529001] ; National Natural Science Foundation of China[81670194] ; National Natural Science Foundation of China[81603270] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Biophysics |
| 语种 | 英语 |
| CSCD记录号 | CSCD:6325942 |
| WOS记录号 | WOS:000440969100007 |
| 出版者 | OXFORD UNIV PRESS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279645]  |
| 专题 | 药物发现与设计中心 |
| 通讯作者 | Zhu, Weiliang; Shi, Jumei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China; 2.Tongji Univ, Canc Ctr, Shanghai 200072, Peoples R China 3.Tongji Univ, Sch Med, Dept Hematol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Yu, Dandan,Zhang, Yong,Chen, Gege,et al. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression[J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA,2018,50(8):782-792. |
| APA | Yu, Dandan.,Zhang, Yong.,Chen, Gege.,Xie, Yongsheng.,Xu, Zhijian.,...&Shi, Jumei.(2018).Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.ACTA BIOCHIMICA ET BIOPHYSICA SINICA,50(8),782-792. |
| MLA | Yu, Dandan,et al."Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression".ACTA BIOCHIMICA ET BIOPHYSICA SINICA 50.8(2018):782-792. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。